{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+mixture", "query": { "intervention": "Saline mixture" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 240, "total_pages": 24, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+mixture&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-07T10:48:11.335Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04019444", "title": "Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Rabies", "Rabies Immunisation" ], "interventions": [ { "name": "ChAd155-RG", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Rabies Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 50, "start_date": "2019-09-19", "completion_date": "2023-03-24", "has_results": true, "last_update_posted_date": "2024-06-03", "last_synced_at": "2026-09-07T10:48:11.335Z", "location_count": 1, "location_summary": "Decatur, Georgia", "locations": [ { "city": "Decatur", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04019444" }, { "nct_id": "NCT02915016", "title": "Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "DNA-HIV-PT123 vaccine", "type": "BIOLOGICAL" }, { "name": "Bivalent Subtype C gp120/MF59 vaccine", "type": "BIOLOGICAL" }, { "name": "Bivalent Subtype C gp120/AS01B vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 334, "start_date": "2016-12-07", "completion_date": "2020-02-12", "has_results": true, "last_update_posted_date": "2022-04-29", "last_synced_at": "2026-09-07T10:48:11.335Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Boston, Massachusetts • New York, New York + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02915016" }, { "nct_id": "NCT05375838", "title": "A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "SARS-CoV-2", "Influenza" ], "interventions": [ { "name": "mRNA-1073", "type": "BIOLOGICAL" }, { "name": "mRNA-1010", "type": "BIOLOGICAL" }, { "name": "mRNA-1273", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "ModernaTX, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 550, "start_date": "2022-05-13", "completion_date": "2022-12-29", "has_results": true, "last_update_posted_date": "2024-02-28", "last_synced_at": "2026-09-07T10:48:11.335Z", "location_count": 14, "location_summary": "Hollywood, Florida • Peoria, Illinois • Sioux City, Iowa + 9 more", "locations": [ { "city": "Hollywood", "state": "Florida" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Sioux City", "state": "Iowa" }, { "city": "Metairie", "state": "Louisiana" }, { "city": "Norfolk", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT05375838" }, { "nct_id": "NCT06841913", "title": "Woodsmoke Exposure, Influenza Infection, and Nasal Immunity", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Smoke Exposure", "Influenza" ], "interventions": [ { "name": "LAIV nasal vaccine is chosen as a model viral infection", "type": "BIOLOGICAL" }, { "name": "Wood smoke", "type": "OTHER" }, { "name": "Placebo for LAIV nasal vaccine is chosen as a model viral infection", "type": "BIOLOGICAL" }, { "name": "Placebo for Wood Smoke (clean Air Exposure)", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 112, "start_date": "2025-09-26", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-09-07T10:48:11.335Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06841913" }, { "nct_id": "NCT04889209", "title": "Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Ad26.COV2.S", "type": "BIOLOGICAL" }, { "name": "BNT162b2", "type": "BIOLOGICAL" }, { "name": "mRNA-1273", "type": "BIOLOGICAL" }, { "name": "mRNA-1273.211", "type": "BIOLOGICAL" }, { "name": "mRNA-1273.222", "type": "BIOLOGICAL" }, { "name": "SARS-CoV-2 rS/M1", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 867, "start_date": "2021-05-28", "completion_date": "2023-06-16", "has_results": true, "last_update_posted_date": "2025-04-20", "last_synced_at": "2026-09-07T10:48:11.335Z", "location_count": 10, "location_summary": "Decatur, Georgia • Baltimore, Maryland • New York, New York + 6 more", "locations": [ { "city": "Decatur", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "Rochester", "state": "New York" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04889209" }, { "nct_id": "NCT01812044", "title": "Postoperative Subtenons Anesthesia for Postoperative Pain in Pediatric Strabismus Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Strabismus" ], "interventions": [ { "name": "subtenons anesthetic - preservative-free bupivacaine 0.75%", "type": "DRUG" }, { "name": "topical anesthetic - 0.5 cc of lidocaine 3.5% ophthalmic gel", "type": "DRUG" }, { "name": "topical control - 0.5 cc of Hypromellose 0.3% gel", "type": "DRUG" }, { "name": "subtenons control - 0.5 cc of Normal Saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "7 Years", "sex": "ALL", "summary": "1 Year to 7 Years" }, "enrollment_count": 57, "start_date": "2013-03", "completion_date": null, "has_results": true, "last_update_posted_date": "2016-04-26", "last_synced_at": "2026-09-07T10:48:11.335Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01812044" }, { "nct_id": "NCT05230511", "title": "Intravesical LGG VS Saline Bladder Wash RCT", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Spinal Cord Injuries", "Neurogenic Bladder" ], "interventions": [ { "name": "Lactobacillus RhamnosusGG", "type": "DRUG" }, { "name": "Saline bladder wash", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medstar Health Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2022-06-13", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2025-08-29", "last_synced_at": "2026-09-07T10:48:11.335Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05230511" }, { "nct_id": "NCT04117074", "title": "Thoracic Epidural Analgesia vs Surgical Site Infiltration With Liposomal Bupivacaine Following Open Gynecologic Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Surgery", "Analgesia" ], "interventions": [ { "name": "Liposomal bupivacaine", "type": "DRUG" }, { "name": "Thoracic epidural analgesia (bupivacaine)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 106, "start_date": "2021-04-14", "completion_date": "2025-03-17", "has_results": true, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-09-07T10:48:11.335Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04117074" }, { "nct_id": "NCT00787761", "title": "Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myeloproliferative Disorders", "Kidney Cancer", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "nonmyeloablative allogeneic HSCT", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Northside Hospital, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "75 Years", "sex": "ALL", "summary": "Up to 75 Years" }, "enrollment_count": 24, "start_date": "2007-04", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2012-10-01", "last_synced_at": "2026-09-07T10:48:11.335Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00787761" }, { "nct_id": "NCT01719237", "title": "Trial Comparing the Onset and Duration of Ultrasound Guided Supraclavicular Nerve Blocks Using Ropivacaine Versus Ropivacaine-Chloroprocaine Mixture", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pain" ], "interventions": [ { "name": "Ropivacine and Chloroprocaine mixture", "type": "DRUG" }, { "name": "Ropivacaine only", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of New Mexico", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2009-08", "completion_date": "2010-11", "has_results": true, "last_update_posted_date": "2023-05-25", "last_synced_at": "2026-09-07T10:48:11.335Z", "location_count": 1, "location_summary": "Albuquerque, New Mexico", "locations": [ { "city": "Albuquerque", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT01719237" } ] }